News Cybin Inc.

Stocks

HELP

CA23256X4075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-07-17 pm EDT			5-day change	1st Jan Change
7.250 ^USD	+2.98%		+5.53%	-11.37%

Jun. 29	Cybin Inc. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
Jun. 25	Helus Pharma Closes $50 Million Underwritten Offering	MT

All News

Mentions Relevance

Jun. 29	Cybin Inc. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
Jun. 29	Cybin : MDA Q4 26 (Exhibit 99.3) Final	PU
Jun. 29	Cybin : Annual Information Form (AIF) March 31 2026 (Exhibit 99.1) Final	PU
Jun. 29	Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results	GL
Jun. 25	Cybin : Financial Statements Q4 26 (Exhibit 99.2) Final	PU
Jun. 25	Helus Pharma Closes $50 Million Underwritten Offering	MT
Jun. 25	Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering	GL
Jun. 24	Helus Pharma Says Enrollment Tops 86% for Phase 3 HLP003 Trial in Major Depressive Disorder	MT
Jun. 24	Helus Pharma Provides Update On Approach Phase 3 Trial Enrollment Progress	CI
Jun. 24	Helus Pharma Prices $50 Million Underwritten Offering	MT
Jun. 24	Helus Pharma™ Announces US$50 Million Underwritten Offering	GL
Jun. 24	Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress	GL
Jun. 11	Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference	GL
Jun. 01	Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York	GL
Apr. 30	Cybin Inc. will Change its Name to Helus Pharma	CI
Apr. 30	Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health	AQ
Apr. 30	Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference	GL
Apr. 28	Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health	GL
Apr. 28	Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health	CI
Apr. 24	FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain	MT
Apr. 23	Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan	GL
Apr. 23	Helus Pharma Announces Scientific Advisory Board Appointments	CI
Apr. 20	Helus Pharma CEO Michael Cola Steps Down	MT
Apr. 20	Helus Pharma says Eric So to resume role as interim chief executive officer	RE
Apr. 20	Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions	GL